Xencor is a clinical-stage biopharmaceutical company focused on discovering and developing engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases who have unmet medical needs. Co. is developing a portfolio of clinical-stage drug candidates from its proprietary XmAb® technology platforms. Drug candidates with Co.'s bispecific Fc domain, both bispecific antibodies and cytokines, in clinical development include: Plamotamab, which is a bispecific antibody that targets CD20 and CD3; XmAb717, which is a bispecific antibody that targets PD-1 and CTLA-4; and Vibecotamab, which is a bispecific antibody that targets CD123 and CD3. The XNCR stock yearly return is shown above.
The yearly return on the XNCR stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2018 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the XNCR annual return calculation with any dividends reinvested as applicable (on ex-dates).
|